Bharat Biotech Executive Chairman Krishna Ella said the goal is to develop solutions to reduce anti-microbial resistance through vaccination. | Photo: Shutterstock
Bharat Biotech on Wednesday announced a collaboration with Alopexx Inc for development and commercialisation of the latter’s broad-spectrum anti-microbial vaccine in India and other low income countries.
As part of the collaboration, the companies will co-develop and commercialise the vaccine — AV0328, in India and other licensed territories, Bharat Biotech said in a statement.
Alopexx would be entitled to a one-time upfront payment and milestone payments, as well as royalties on future sales of AV0328 in the licensed territories, it added.
“Our goal is to develop solutions to reduce anti-microbial resistance through vaccination. This collaboration aligns with our mission to provide safe, affordable, and high-quality vaccines to combat infectious diseases globally,” Bharat Biotech Executive Chairman Krishna Ella said.
Â
Alopexx CEO Daniel Vlock said, this collaboration brings the company one step closer to addressing the critical need for affordable, broad-spectrum antimicrobial solutions, especially in low-and middle-income countries.
“The broad and breakthrough potential of our platforms in treating a wide array of bacterial, fungal, and parasitic infections represents a transformative approach to combating infectious diseases on a global scale,” Vlock added.
A phase I, first-in-human trial has been completed, demonstrating that AV0328 is well-tolerated with no serious adverse events observed, the statement said.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
First Published: Sep 11 2024 | 2:12 PM IST
